The Guzman Y Gomez Ltd (ASX: GYG) dividend has been announced along with the FY26 result. The numbers give shareholders a cash payout, along with insights into company performance.

Excluding the US operations that are being closed, the company reported network sales growth of 17.9% to $1.38 billion, revenue increased 21.8% to $520.4 million, underlying operating profit (EBITDA) rose 28.7% to $85 million, and statutory net profit soared 31.6% to $40.6 million.

The company also noted that it opened 35 new restaurants across Australia and Asia this year and added 62 new sites to its Australian development pipeline.

With its profit generation in Australia, the business was able to declare a large final dividend with the FY26 result.

Guzman Y Gomez dividend

GYG has declared an FY26 final dividend of 40.6 cents per share and includes a special dividend of 14.4 cents per share.

The special dividend retrospectively increases the implied dividend payout ratio for the interim dividend (which was 7.4 cents per share) to an implied dividend payout ratio of around 90% of underlying earnings to reflect the removal of US losses from its earnings.

The increase of the dividend also reflects an increase in earnings and reduced Guzman Y Gomez share count after the completion of its share buyback.

GYG’s board of directors also approved the extension of the share buyback program to a further $100 million.

At the time of writing, following the jump of the Guzman Y Gomez share price, the final dividend represents a dividend yield of 1.6%, excluding franking credits, and 2.2%, including franking credits.

When will this be paid?

Before getting to the exciting payment date for the upcoming GYG dividend, we need to look at the ex-dividend date.

The ex-dividend date is the cut-off day for investors who want to receive the payout. Investors need to own shares before this date to be entitled to the dividend.

Guzman Y Gomez’s ex-dividend date for the FY26 final dividend is 15 September 2026, which is less than a month away. Therefore, investors have until the end of trading on 14 September 2026 to buy shares.

The dividend will then be paid on 30 September 2026, which is just over a month away, so investors won’t have a long time to wait.

There is no dividend reinvestment plan (DRP) relating to this upcoming dividend.

What is the full-year GYG dividend yield?

Based on the interim and final dividends, the business will deliver a full-year dividend of 48 cents per share. At the time of writing, that translates into a dividend yield of 1.9%, excluding franking credits, and 2.7%, including franking credits.

The post Everything you need to know about the Guzman Y Gomez dividend appeared first on The Motley Fool Australia.

More reading

• Why Guzman Y Gomez, Pro Medicus and James Hardie shares are turning heads on Friday
• Guzman y Gomez delivers record FY26 results, launches new buyback
• 2 top ASX shares to buy and hold for the next decade
• 5 ASX shares downgraded by brokers this week
• Consumer staples and discretionary shares are rallying: These stocks could be top buys

Motley Fool contributor Tristan Harrison has positions in Guzman Y Gomez. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Three fast-rising S&P/ASX 200 Index (ASX: XJO) gold stocks released their full-year FY 2026 earnings results this morning.

And investors have responded by bidding all three stocks higher as we head into the Friday lunch hour, despite the 0.2% fall in the ASX 200 at this same time.

Here’s what’s happening.

Ramelius Resources Ltd (ASX: RMS)

Ramelius Resources shares are up 0.8% at time of writing, swapping hands for $3.95 apiece.

That sees this ASX 200 gold stock up 37% since this time last year.

For FY 2026, Ramelius reported a 1% year-on-year increase in revenue to $1.03 billion.

Underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of $765 million were down 7%.

On the bottom line, the gold miner reported a 33% year-on-year decline in underlying net profit after tax (NPAT) to $320 million.

Profits and earnings were impacted in part by the lower production volumes associated with the completion of operations at the company’s Edna May project.

Regis Resources Ltd (ASX: RRL)

Regis Resources shares are also attracting attention today after the miner released its FY 2026 results.

Shares in the ASX 200 gold stock are up 3.2%, trading for $8.49 each. That sees the Regis Resources share price up 90% in 12 months.

Over the 12 months, Regis Resource produced 379,050 ounces of gold at an all-in sustaining cost (AISC) of $2,945 per ounce.

The miner sold 373,879 ounces over the year, receiving an average price of $6,283 per ounce.

This saw revenue increase by 43% from FY 2025 to $2.35 billion. And it helped the miner set a new record NPAT of $715 million, up a whopping 181% year on year.

With profits soaring, management declared a fully-franked final dividend of 20 cents per share.

Regis ended the year with cash and bullion holdings of $1.18 billion, up $667 million from the close of FY 2025.

Genesis Minerals Ltd (ASX: GMD)

The third ASX 200 gold stock making moves following the release of its full-year results is Genesis Minerals.

Genesis Minerals shares are up 2%, trading for $8.17 apiece. That puts the share price up 93% since this time last year.

FY 2026 was an eventful period for the miner, with gold production up 33% from FY 2025 to 285,402 ounces. Genesis produced the gold at an AISC of $2,670 per ounce.

And earnings hit a new record high, with the company reporting a 110% lift in EBITDA to $952 million.

Profits surged as well, with underlying NPAT up 147% to $547 million.

And with profits rocketing, the ASX 200 gold stock delivered its first ever dividend, fully franked at 5 cents per share.

Genesis Minerals ended the financial year with cash and equivalents of $520 million, up 81% from last year.

The post 3 ASX 200 gold stocks jumping higher on big news today appeared first on The Motley Fool Australia.

More reading

• Ramelius Resources reports profit drop, expands growth plans in FY26 earnings
• Regis Resources delivers record FY26 profit and dividends
• Genesis Minerals FY26 earnings: profit, growth, maiden dividend
• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Tuesday

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are tumbling on Friday, falling 8% to $16. That is a sharp reversal after the stock climbed 5% on Thursday following the release of its half-year results.

Despite today’s decline, Telix shares remain up around 42% year to date, although they are down roughly 4% over the past 12 months.

So, why are Telix shares plunging despite another strong set of numbers?

Telix delivers strong first-half growth

On Thursday, Telix reported a 22% year-on-year increase in revenue to US$477 million, tracking towards the upper end of its FY26 guidance. The company’s gross margin improved to 55%, while its Precision Medicine segment delivered an impressive 65% margin.

Adjusted EBITDA jumped 146% to US$52 million, while profit after tax reached US$38 million. That included a US$40 million payment from Regeneron.

Operationally, Precision Medicine remained the key growth engine, with flagship products Illuccix and Gozellix continuing to gain market share.

The biotech company also achieved several important clinical milestones, including completing enrolment for late-stage trials and making regulatory progress across the US, China, Europe, and Japan.

The business is simultaneously expanding its global manufacturing footprint through new and upgraded facilities in Australia, Belgium, Japan, and the US.

Telix shares reaffirmed FY26 revenue and other income guidance of more than US$1 billion, with Research & Development expenditure expected to come in between US$230 million and US$270 million.

Why are Telix shares falling?

One clue for the plummeting Telix share price comes from Bell Potter.

The leading broker was pleased with Telix’s first-half performance, but warned that competition could weigh on revenue later in the year. It said:

1H26 increased by 22% to $477m, dominated by US sales of PSMA imaging agents. FY26 revenue guidance range is unchanged at $950m – $970m with the company guiding to the upper end. We expect the launch of a competitor product (TruVu – Lantheus) will impact 4Q26 revenues, nevertheless, the top end of the guidance is realistic. We do not anticipate a change in guidance irrespective of 3Q26 revenues.

Importantly, Bell Potter now believes Telix shares are approaching fair value. As a result, it has downgraded the stock from buy to hold, while retaining its $19 price target.

That target still represents potential upside of roughly 17% from $16, but the downgrade may be giving investors pause after Telix’s substantial gains this year.

In other words, today’s sell-off may have less to do with disappointing results and more to do with valuation, competition, and expectations for future growth.

The post Telix shares are tumbling. Is the stock finally at fair value? appeared first on The Motley Fool Australia.

More reading

• Why were Telix shares just downgraded?
• 5 things to watch on the ASX 200 on Friday
• 7 ASX 200 shares with reaffirmed buy ratings this week
• Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress
• These are the 10 most shorted ASX shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.